⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KURA News
Kura Oncology, Inc.
Form 8-K
sec.gov
KURA
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
globenewswire.com
KURA
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
KURA
BMY
IPHA
MRK
MNPR
JAZZ
MOLN
LLY
GSK
AGEN
PFE
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
globenewswire.com
KURA
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
globenewswire.com
KURA
Form 8-K
sec.gov
KURA
Kura Oncology Reports First Quarter 2026 Financial Results
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
globenewswire.com
KURA
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
globenewswire.com
KURA